Sagimet Biosciences (STU:0O2) Debt-to-Revenue : N/A (As of Mar. 2026)


STU:0O2 Sagimet Biosciences Inc STU:0O2
10 GF Score
Price €6.54
! 2 Warning Signs
View Full Analysis

What is Sagimet Biosciences Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Sagimet Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was €0.03 Mil. Sagimet Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was €0.00 Mil. Sagimet Biosciences's annualized Revenue for the quarter that ended in Mar. 2026 was €0.00 Mil.

Sagimet Biosciences Debt-to-Revenue Historical Data

* Premium members only.

The historical data trend for Sagimet Biosciences's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sagimet Biosciences Debt-to-Revenue Chart

Sagimet Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-Revenue
Get a 7-Day Free Trial N/A N/A 0.03 N/A N/A

Sagimet Biosciences Quarterly Data
Dec20 Mar21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A N/A N/A N/A N/A

STU:0O2 vs EDIT, AUTL, FBRX: Debt-to-Revenue Comparison

For the Biotechnology subindustry, Sagimet Biosciences's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sagimet Biosciences Debt-to-Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Sagimet Biosciences's Debt-to-Revenue falls into.


STU:0O2
10GF Score
Sagimet Biosciences Inc STU:0O2
Debt-to-Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sagimet Biosciences Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Sagimet Biosciences's Debt-to-Revenue for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.067 + 0) / N/A
=N/A

Sagimet Biosciences's annualized Debt-to-Revenue for the quarter that ended in Mar. 2026 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.034 + 0) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Mar. 2026) Revenue data.

Sagimet Biosciences Business Description

Other Exchanges SGMT:USA
Address 155 Bovet Road, Suite 303, San Mateo, CA, USA, 94402
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
10GF Score

Get the complete analysis for STU:0O2

Debt-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€6.54
Price